Published in Thromb Res on March 25, 2009
Polymorphic cytochrome P450 enzymes (CYPs) and their role in personalized therapy. PLoS One (2013) 0.91
Risk factors for clopidogrel resistance in patients with ischemic cerebral infarction and the correlation with ABCB1 gene rs1045642 polymorphism. Exp Ther Med (2014) 0.76
CYP 450 2C19 polymorphisms in Indian patients with coronary artery disease. Indian Heart J (2013) 0.76
Aspirin and clopidogrel resistance using the cone and plate(let) analyser in Indian patients with coronary artery disease. Heart Asia (2014) 0.75
Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med (2012) 6.24
The transradial approach to percutaneous coronary intervention: historical perspective, current concepts, and future directions. J Am Coll Cardiol (2010) 1.98
Adoption of radial access and comparison of outcomes to femoral access in percutaneous coronary intervention: an updated report from the national cardiovascular data registry (2007-2012). Circulation (2013) 1.69
Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies. Blood (2004) 1.62
Safety and performance of targeted renal therapy: the Be-RITe! Registry. J Endovasc Ther (2009) 1.54
Safety of transradial cardiac catheterization in patients with end-stage liver disease. Catheter Cardiovasc Interv (2013) 1.47
Use of the REG1 anticoagulation system in patients with acute coronary syndromes undergoing percutaneous coronary intervention: results from the phase II RADAR-PCI study. EuroIntervention (2014) 1.42
The use of vascular closure devices and impact on major bleeding and net adverse clinical events (NACEs) in balloon aortic valvuloplasty: a sub-analysis of the BRAVO study. Catheter Cardiovasc Interv (2013) 1.40
The kinetics of integrilin limited by obesity: a multicenter randomized pharmacokinetic and pharmacodynamic clinical trial. Am Heart J (2011) 1.39
Impact of CMS coverage decision on access to transcatheter aortic valve replacement. Catheter Cardiovasc Interv (2014) 1.38
Management of paravalvular regurgitation after Edwards SAPIEN transcatheter aortic valve replacement: management of paravalvular regurgitation after TAVR. Catheter Cardiovasc Interv (2013) 1.38
A tale of two pressures: a case of pseudo-prosthetic mitral valve stenosis. Catheter Cardiovasc Interv (2011) 1.38
Sequential high-dose ifosfamide, carboplatin and etoposide with rituximab for relapsed Hodgkin and large B-cell non-Hodgkin lymphoma: increased toxicity without improvement in progression-free survival. Leuk Lymphoma (2009) 1.38
B cells from patients with chronic GVHD are activated and primed for survival via BAFF-mediated pathways. Blood (2012) 1.15
Phase 1b randomized study of antidote-controlled modulation of factor IXa activity in patients with stable coronary artery disease. Circulation (2008) 1.14
Role of procoagulant microparticles in mediating complications and outcome of acute liver injury/acute liver failure. Hepatology (2013) 1.11
Predictive factors, management, and clinical outcomes of coronary obstruction following transcatheter aortic valve implantation: insights from a large multicenter registry. J Am Coll Cardiol (2013) 1.02
Regional outcomes after admission for high-risk non-ST-segment elevation acute coronary syndromes. Am J Med (2006) 1.02
Latino patients' preferences for medication information and pharmacy services. J Am Pharm Assoc (2003) (2009) 1.02
Successful treatment of diffuse alveolar hemorrhage with activated factor VII. Ann Intern Med (2004) 0.99
The contribution of hypertension to black-white differences in likelihood of coronary artery disease detected during elective angiography. Am J Hypertens (2010) 0.98
A prospective randomized clinical trial of the use of fluoroscopy in obtaining femoral arterial access. J Invasive Cardiol (2009) 0.97
Aortic counterpulsation: a review of the hemodynamic effects and indications for use. Catheter Cardiovasc Interv (2006) 0.96
Pharmacokinetics of ganciclovir after oral valganciclovir versus intravenous ganciclovir in allogeneic stem cell transplant patients with graft-versus-host disease of the gastrointestinal tract. Biol Blood Marrow Transplant (2006) 0.94
ST-T wave abnormality in lead aVR and reclassification of cardiovascular risk (from the National Health and Nutrition Examination Survey-III). Am J Cardiol (2013) 0.90
Pegnivacogin results in near complete FIX inhibition in acute coronary syndrome patients: RADAR pharmacokinetic and pharmacodynamic substudy. Eur Heart J (2011) 0.87
Racial differences among high-risk patients presenting with non-ST-segment elevation acute coronary syndromes (results from the SYNERGY trial). Am J Cardiol (2006) 0.87
Nucleic acid aptamers as antithrombotic agents: Opportunities in extracellular therapeutics. Thromb Haemost (2010) 0.86
The transaortic approach for transcatheter aortic valve replacement: initial clinical experience in the United States. J Am Coll Cardiol (2013) 0.85
Early reperfusion and late clinical outcomes in patients presenting with acute myocardial infarction randomly assigned to primary percutaneous coronary intervention or streptokinase. Am Heart J (2003) 0.84
Differences in treatment patterns and outcomes between Hispanics and non-Hispanic Whites treated for ST-segment elevation myocardial infarction: results from the NCDR ACTION Registry-GWTG. J Am Coll Cardiol (2012) 0.84
Coagulopathy of acute liver failure. Clin Liver Dis (2009) 0.84
Isolated nonspecific ST-segment and T-wave abnormalities in a cross-sectional United States population and Mortality (from NHANES III). Am J Cardiol (2012) 0.83
Pharmacotherapy in chronic kidney disease patients presenting with acute coronary syndrome: a scientific statement from the American Heart Association. Circulation (2015) 0.81
Liposomal daunorubicin (DaunoXome) plus dexamethasone for patients with multiple myeloma. A phase II International Oncology Study Group study. Cancer (2002) 0.81
Safety of adjunctive intracoronary thrombolytic therapy during complex percutaneous coronary intervention: initial experience with intracoronary tenecteplase. Catheter Cardiovasc Interv (2005) 0.79
Influence of hospital volume on outcomes of percutaneous atrial septal defect and patent foramen ovale closure: a 10-years US perspective. Catheter Cardiovasc Interv (2015) 0.79
The everlasting effect of primary percutaneous coronary intervention--even after transport? Can J Cardiol (2003) 0.79
Aortic balloon valvuloplasty and severe systolic dysfunction. Is there a danger zone? Catheter Cardiovasc Interv (2014) 0.78
Extent of ST-segment depression and cardiac events in non-ST-segment elevation acute coronary syndromes. Eur Heart J (2005) 0.78
Unfractionated heparin reduces the anti-platelet effects of abciximab but not eptifibatide during PCI. Clin Appl Thromb Hemost (2006) 0.78
Measuring and treating serum lipids in patients in a chest pain observation unit. Am J Cardiol (2007) 0.77
Percutaneous retrograde left ventricular assist support for interventions in patients with aortic stenosis and left ventricular dysfunction. Catheter Cardiovasc Interv (2012) 0.77
An expanded phase I/II trial of cyclophosphamide, etoposide, and carboplatin plus total body irradiation with autologous marrow or stem cell support for patients with hematologic malignancies. Biol Blood Marrow Transplant (2003) 0.77
Latinos' sources of medication and medication information in the United States and their home countries. Patient Educ Couns (2008) 0.77
Rare cause of ureteral obstruction. Urology (2005) 0.77
Intravesicular cidofovir for the management of BK virus-associated cystitis. Biol Blood Marrow Transplant (2009) 0.77
The REG1 anticoagulation system: a novel actively controlled factor IX inhibitor using RNA aptamer technology for treatment of acute coronary syndrome. Future Cardiol (2012) 0.77
Clinical predictors and characteristics of patients with chronic liver disease and intrapulmonary shunts. Clin Cardiol (2005) 0.77
Role of hematopoietic stem cell transplant in the management of follicular lymphoma. Oncologist (2009) 0.76
Infusional mitoxantrone plus bolus melphalan as a stem cell transplant conditioning regimen for multiple myeloma. Cancer Invest (2011) 0.76
Bivalirudin and transradial access--the end of the bleeding era for catheterization procedures? J Invasive Cardiol (2011) 0.75
Left or right, transradial access for all. J Invasive Cardiol (2010) 0.75
Intracoronary thrombus a sticky problem. JACC Cardiovasc Interv (2010) 0.75
Has the gender gap in percutaneous coronary intervention-related mortality narrowed? Catheter Cardiovasc Interv (2012) 0.75
Drug-eluting stents in acute myocardial infarction: is science catching up with practice? JAMA (2005) 0.75
Percutaneous left ventricular assist devices--still waiting for the final word. Catheter Cardiovasc Interv (2011) 0.75
Cerebral protection against left ventricular thrombus during transcatheter aortic valve replacement in a patient with critical aortic stenosis. Tex Heart Inst J (2013) 0.75
Non-pharmacologic stroke prevention in atrial fibrillation: an issue without closure. Catheter Cardiovasc Interv (2013) 0.75
Therapy in ST-elevation myocardial infarction: reperfusion strategies, pharmacology and stent selection. Curr Treat Options Cardiovasc Med (2014) 0.75
Reversal of end stage renal disease in patient with transcatheter aortic valve replacement. Catheter Cardiovasc Interv (2013) 0.75
Anticoagulation for percutaneous coronary intervention: a contemporary review. Curr Opin Cardiol (2015) 0.75
A case report of simultaneous thrombosis of two coronary artery stents in association with clopidogrel resistance. Clin Cardiol (2007) 0.75
Presence of anti-viral and anti-parasitic antibodies and cardiovascular mortality: insights from NHANES III. Int J Cardiol (2013) 0.75
Effect of bivalirudin on aortic valve intervention outcomes study: a two-centre registry study comparing bivalirudin and unfractionated heparin in balloon aortic valvuloplasty. EuroIntervention (2014) 0.75
Dual percutaneous mechanical circulatory support as a bridge to recovery in fulminant myocarditis. ASAIO J (2011) 0.75
Predictors of J-point elevation in a cross sectional US cohort. Int J Cardiol (2013) 0.75
Successful transradial retrieval of an embolized guidewire during transradial vascular access. Catheter Cardiovasc Interv (2014) 0.75
Simultaneous testing of the heparin effect on the soluble phase and platelet component of hemostasis. Am J Med Sci (2003) 0.75
Electrocardiographic comparison of myocardial salvage with primary revascularization versus thrombolysis in inferior myocardial infarction. J Electrocardiol (2002) 0.75
Safety of very early sheath removal in patients treated with REG1 for acute coronary syndromes: insights from the RADAR trial. J Invasive Cardiol (2013) 0.75
Vaccination Serology Status and Cardiovascular Mortality: Insight from NHANES III and Continuous NHANES. Postgrad Med (2015) 0.75
Facilitated percutaneous coronary intervention in acute myocardial infarction: attractive concept but difficult to prove! Am Heart Hosp J (2004) 0.75
Clinical outcomes with on-label and off-label use of the transcatheter heart valve in the United States. Catheter Cardiovasc Interv (2014) 0.75
Impact of iodinated contrast injections on percent diameter coronary arterial stenosis and implications for trials of intracoronary pharmacotherapies in patients with ST-elevation myocardial infarction. Am J Cardiol (2007) 0.75
The contrast media iohexol causes vasoconstriction of the proximal left anterior descending coronary artery: implications for appropriate stent sizing. Angiology (2008) 0.75
Electrocardiographic abnormalities and reclassification of cardiovascular risk: insights from NHANES-III. Am J Med (2013) 0.75
Contemporary Management of Cardiogenic Shock: A Scientific Statement From the American Heart Association. Circulation (2017) 0.75
Mechanical thrombectomy options in complex percutaneous coronary interventions. Catheter Cardiovasc Interv (2006) 0.75